Zacks Investment Research downgraded shares of AnaptysBio (NASDAQ:ANAB) from a hold rating to a sell rating in a research report sent to investors on Friday.
According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
ANAB has been the subject of several other research reports. Royal Bank of Canada restated a hold rating and issued a $84.00 target price on shares of AnaptysBio in a research note on Wednesday, August 8th. Jefferies Financial Group restated a buy rating and issued a $121.00 target price on shares of AnaptysBio in a research note on Tuesday, August 7th. Credit Suisse Group set a $147.00 target price on AnaptysBio and gave the stock a buy rating in a research note on Thursday, September 27th. Wedbush restated an outperform rating and issued a $138.00 target price on shares of AnaptysBio in a research note on Tuesday, September 18th. Finally, Cantor Fitzgerald set a $140.00 target price on AnaptysBio and gave the stock a buy rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus price target of $130.50.
AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.05. The company had revenue of $5.00 million during the quarter. Equities research analysts anticipate that AnaptysBio will post -2.72 EPS for the current year.
Institutional investors and hedge funds have recently modified their holdings of the company. Partner Investment Management L.P. boosted its position in shares of AnaptysBio by 82.8% during the 2nd quarter. Partner Investment Management L.P. now owns 1,709 shares of the biotechnology company’s stock valued at $121,000 after acquiring an additional 774 shares during the last quarter. Great West Life Assurance Co. Can boosted its position in shares of AnaptysBio by 65.9% during the 2nd quarter. Great West Life Assurance Co. Can now owns 2,057 shares of the biotechnology company’s stock valued at $146,000 after acquiring an additional 817 shares during the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of AnaptysBio during the 3rd quarter valued at about $203,000. Quantitative Systematic Strategies LLC bought a new stake in shares of AnaptysBio during the 2nd quarter valued at about $211,000. Finally, United Services Automobile Association boosted its position in shares of AnaptysBio by 27.9% during the 2nd quarter. United Services Automobile Association now owns 3,138 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 685 shares during the last quarter.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Further Reading: What are the Benefits of Index Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.